Liquid biopsy in clinical pratice of non-small cell lung cancer (NSCLC): A multi-institutional experience
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz260.086
Abstract: Abstract Background Circulating tumor DNA (ctDNA) from liquid biopsy is a source of tumor genetic material for EGFR testing in NSCLC when resistance to I-II generations TKI-therapies occurs or upfront, in absence of tissue biopsy.… read more here.
Keywords: biopsy; biopsy clinical; liquid biopsy; oncology ... See more keywords
An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.27_suppl.318
Abstract: 318 Background: ASCO Quality Oncology Practice Initiative (QOPI) encourages hospitals to determine if patients (pts) with stage IV NSCLC adenocarcinoma have activating EGFR mutations. Guidelines recommend tumor testing to identify ALK, BRAF, EGFR, ROS1 and… read more here.
Keywords: tool identify; nlp tool; stage nsclc; oncology ... See more keywords
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13143641
Abstract: Simple Summary The presence of an EGFR activating mutation in tumors of non-small-cell lung cancer patients enables effective targeted therapy towards EGFR. Studies that describe a nationwide uptake of EGFR testing, the impact of the… read more here.
Keywords: egfr; egfr mutation; egfr mutations; impact ... See more keywords
Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29100624
Abstract: Introduction: Patients with advanced-stage non-small cell lung cancer (NSCLC) may benefit from a short time-to-treatment (TTT). Predictive biomarker testing is performed prior to treatment, as recommended by various international expert consensus bodies. Genetic testing is… read more here.
Keywords: time; egfr testing; idylla egfr; treatment ... See more keywords
Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists.
Sign Up to like & getrecommendations! Published in 2017 at "Current oncology"
DOI: 10.3747/co.24.3266
Abstract: BACKGROUND Testing for mutation of the EGFR (epidermal growth factor receptor) gene is a standard of care for patients with advanced nonsquamous non-small-cell lung cancer (nsclc). To improve timely access to EGFR results, a few… read more here.
Keywords: nonsquamous non; non small; reflex testing; egfr testing ... See more keywords